



IMAGE-ARPKD: IMAGING ASSESSMENTS OF ARPKD KIDNEY DISEASE PROGRESSION

WHAT IS THE GOAL?

This study is being done to better understand how certain MRI techniques can be applied to measuring disease progression in patients with autosomal recessive polycystic kidney disease (ARPKD).

WHO CAN BE A PART OF THE STUDY?

- Ages 6 and older
- Ability to lie in an MRI scanner for up to 60 minutes
- Normal to moderately decreased kidney function (chronic kidney disease stages 1-3)
- Clinical diagnosis of ARPKD
- No history of transplantation of any type
- Able to safely have an MRI (including no pacemakers, implants, or a history of difficulties with having an MRI).

WHAT WILL PARTICIPANTS BE ASKED TO DO?

- There will be 4 study visits over approximately 4 years. Each study visit lasts about 6 hours.
- Participants must fast for 6 to 8 hours the night before each study visit
- At each visit, participants will:
 - Have a blood draw
 - Provide a urine sample
 - Undergo a measured GFR
 - This test accurately measures kidney function using IVs to inject a small amount of non-radioactive dye (iohexol) and draw blood. Iohexol is commonly used as contrast for imaging studies.
 - Have an MRI
 - The MRI does not require any IV contrast and is safe for patients with kidney disease.

Procedures will be done at the Children's Hospital of Philadelphia. Travel costs will be covered by the study.

I WANT TO HELP! WHO DO I CALL?

For more information, please contact Dr. Erum Hartung's study team at:

ARPKD_Studies@chop.edu